Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Scynexis Inc (SCYX)

Scynexis Inc (SCYX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,759
  • Shares Outstanding, K 97,417
  • Annual Sales, $ 120 K
  • Annual Income, $ -53,710 K
  • 60-Month Beta 1.82
  • Price/Sales 678.05
  • Price/Cash Flow N/A
  • Price/Book 6.36
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.55
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/13/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5000 +71.96%
on 03/18/20
0.9800 -12.27%
on 03/09/20
-0.1203 (-12.27%)
since 03/06/20
3-Month
0.5000 +71.96%
on 03/18/20
1.1900 -27.75%
on 02/19/20
-0.1902 (-18.11%)
since 01/08/20
52-Week
0.5000 +71.96%
on 03/18/20
1.9000 -54.75%
on 04/09/19
-0.9402 (-52.23%)
since 04/08/19

Most Recent Stories

More News
SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Nkechi Azie, SCYNEXIS's...

SCYX : 0.8599 (+0.01%)
SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update

-- Nearing completion of Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as vaginal yeast infection; second of two studies...

SCYX : 0.8599 (+0.01%)
SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference

-- SCYNEXIS is conducting two clinical trials for patients suffering from Aspergillus infections: FURI evaluating ibrexafungerp as salvage therapy (alone or in combination) and SCYNERGIA evaluating ibrexafungerp...

SCYX : 0.8599 (+0.01%)
SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has completed patient enrollment...

SCYX : 0.8599 (+0.01%)
Will SCYNEXIS Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in SCYNEXIS.

SCYX : 0.8599 (+0.01%)
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from its second interim...

SCYX : 0.8599 (+0.01%)
SCYNEXIS Appoints Business Development Veteran Philippe Tinmouth to its Board of Directors

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of accomplished business...

VRTX : 249.89 (+0.90%)
SCYX : 0.8599 (+0.01%)
SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants

SCYNEXIS, Inc. (NASDAQ : SCYX) today announced the closing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to purchase up to 38,888,889 shares...

SCYX : 0.8599 (+0.01%)
SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants

SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the pricing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to purchase up to 38,888,889 shares...

SCYX : 0.8599 (+0.01%)
SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

SCYNEXIS, Inc. (NASDAQ : SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants. In addition, SCYNEXIS expects to grant the underwriter a...

SCYX : 0.8599 (+0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SCYX with:

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

2nd Resistance Point 0.9133
1st Resistance Point 0.8865
Last Price 0.8599
1st Support Level 0.8265
2nd Support Level 0.7933

See More

52-Week High 1.9000
Fibonacci 61.8% 1.3652
Fibonacci 50% 1.2000
Fibonacci 38.2% 1.0348
Last Price 0.8599
52-Week Low 0.5000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar